Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$6.83 USD
+0.10 (1.49%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.84 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
Fulcrum Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
FULC 6.83 +0.10(1.49%)
Will FULC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
New Strong Buy Stocks for November 12th
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Other News for FULC
RBC Capital Maintains Rating and Raises Price Target for Fulcrum Therapeutics (FULC) | FULC ...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug
FULC Stock: Fulcrum Therapeutics Upgraded to Buy by HC Wainwright | FULC Stock News
Fulcrum Therapeutics (FULC) Receives Upgrade to Buy with Price Target Set at $12